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ABSTRACT
Edible bird’s nest (EBN) is an ancient food that had been consumed by Chinese people for well-being purposes. 
Nevertheless, the effect of EBN on cholesterol metabolism is poorly studied. Since the cholesterol is primarily being 
metabolized in the liver, HepG2 cell lines was selected as the model for in-vitro preliminary assessment. Our EBN 
extract (EBNE) showed 71% cell viability in HepG2 cell lines, even at the highest dose (1.5 mg/mL). Simultaneously, EBNE 
was significantly up-regulated the LDL-R gene expression via suppression of HMGCR at the highest concentration. 
Besides that, ACAT2 was up-regulated significantly to allow exogenous cholesterol storage. Expression analysis of 
these genes were correlated with high immunofluorescence distribution of the LDL-R and LDs compared to other 
treatment groups. Consistent with gene expression and immunofluorescence staining, intrahepatocellular cholesterol 
concentration was increased significantly at the highest dose of EBNE. The EBNE had significantly improved 
cholesterol metabolism in the HepG2 cell line via suppression of the HMGCR gene and subsequently up-regulated 
LDL-R gene expression at the highest dose. Therefore, this study provides an insight to understand the effect of EBNE 
in improving cholesterol metabolism. 
Keywords: 3-hydroxy-3-methylglutharaldehyde CoA reductase (HMGCR); cholesterol metabolism; edible bird’s nest 
(EBN); HepG2; low-density lipoprotein receptor (LDL-R) 
ABSTRAK
Sarang burung Walet (EBN) merupakan makanan tradisi yang diamalkan oleh masyarakat China bagi tujuan kesihatan. 
Dalam pada itu, kesan EBN ke atas metabolisme kolesterol masih belum dikaji dengan terperinci sehingga kini. Organ 
hati memainkan peranan sebagai organ utama di dalam tubuh badan manusia yang melibatkan metabolisme kolesterol 
terutamanya pada hati. Justeru, sel HepG2 iaitu sel hepatosit hati dipilih sebagai model kajian rintis terhadap 
peranan EBN pada organ hati secara in-vitro. Menerusi kajian yang telah dijalankan terhadap ekstrak EBN (EBNE) 
menemukan bahawa, walaupun dos tersebut paling tinggi (1.5 mg/mL) digunakan, namun kelangsungan sel HepG2 
hidup adalah sebanyak 71%. Pada masa yang sama, EBNE telah meningkatkan pengekspresan gen LDL-R dengan ketara 
melalui perencatan gen HMGCR pada EBNE berkepekatan tertinggi. Manakala, ACAT2 turut jelas sekali meningkat 
dalam memainkan peranan ia membolehkan penyimpanan kolesterol eksogenus di dalam sel. Analisis ekspresi gen-
gen ini berkait dengan taburan imunopendarfluor LDL-R dan LD yang tinggi berbanding dengan kumpulan rawatan 
seumpamanya. Rentetan kajian pengekspresan gen dan pewarnaan imunopendarfluor, didapati kepekatan kolesterol 
intrahepatosel telah meningkat pada dos EBNE yang tertinggi nyata sekali. EBNE telah menambahbaik metabolisme 
kolesterol di dalam sel HepG2 melalui perencatan gen HMGCR serta meningkatkan pengekspresan gen LDL-R pada 
dos tertinggi. Lantaran itu, kajian ini memberikan pemahaman mengenai kesan EBNE dalam menambahbaikkan 
metabolisme kolesterol di dalam tubuh badan manusia.
Kata kunci: 3-hidroksi-3-metilglutharaldehid CoA reduktase (HMGCR); metabolisme kolesterol; sarang burung walet 
(EBN); HepG2; reseptor lipoprotein berketumpatan rendah (LDL-R) 
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INTRODUCTION
The use of edible bird’s nest (EBN) in traditional Chinese 
medicine has been documented since the Tang Dynasty 
(618-907 CE). EBN is used as a natural supplement that 
possesses various medicinal benefits towards human 
wellness, including anti-viral, anti-inflammatory, immune 
modulator, respiratory supplement, anti-aging and 
metabolic stimulant (Haghani et al. 2016; Marcone 2005). 
EBN derived from salivary secretion of two sublingual’s 
palaeotropical swiftlets (Looi & Omar 2016); in particular 
male swiftlets during mating season (Ma & Liu 2012). 
Most of the Chinese community would consume this 
tonic food in the form of bird’s nest soup and serve as a 
traditional remedy (Ma & Liu 2012). In general, proximate 
analysis of EBN from Aerodramus genus nest consists of 
proteins (62.0-63.0%), carbohydrates (25.62-27.26%), 
ash (2.1%), and lipid (0.14-1.28%) (Yu-Qin et al. 2000). 
Most of the proteins and carbohydrates found in the form 
of glycoproteins such as sialic acid, galactosamine and 
glucosamine, which linked via carbohydrate-peptide 
linkages (Ma & Liu 2012). In the matrix-rich glycoproteins 
of EBN, sialic acid is the major essential sugar component 
in the EBN, which constitute of 9-11% (Colombo et al. 
2003; Yida et al. 2015a) and this glycoprotein served as 
important metabolite in improving cholesterol metabolism 
(Lindbohm et al. 2000; Millar 2001). Scientifically, the 
EBN was claimed as a complete food ingredient that can 
be consumed by the human (Chua et al. 2014).
Low-density lipoprotein cholesterol (LDL-C) 
or commonly termed as a bad cholesterol can lead 
to cardiovascular disease (CVD) (Gradinaru et al. 
2015). When LDL-C is excessively circulating in the 
bloodstream, human body will be stimulated to express 
the LDL receptor (LDL-R) on the plasma membrane 
particularly hepatocytes for excess LDL-C internalization 
(Charlton-Menys & Durrington 2007). Liver serves as the 
major internal organ in metabolizing excess cholesterol 
in bloodstream (Rogers et al. 2015; Shimano & Sato 
2017) Subsequently, degraded LDL-C will be stored in 
the lipid droplet in form of cholesterol ester for future 
use under catalyzation of acyl-coenzyme A: cholesterol 
acyltransferase 2 (ACAT2) (Chang et al. 2009; Rogers et 
al. 2015). For past decade, researchers have been targeting 
cholesterol rate-limiting enzyme called 3-hydroxy-3-
methyglutaryl-coenzyme A reductase (HMGCR) to reduce 
high cholesterol in the blood (Steinberg 2006). To date, 
CVD is a disease leading in death worldwide, particularly 
in developed and developing country (Ladeiras-Lopes et 
al. 2015). The primary cause of CVD is due to cumulative 
effect of high cholesterol in the blood, which eventually 
lead to plaque formation, and this disorder can be termed as 
atherosclerosis (Chan et al. 2014). High blood cholesterol 
can be medically managed by consumption of anti-
cholesterol drugs (Ladeiras-Lopes et al. 2015). 
In recent years, many nutraceutical researchers are 
promoting homeopathic medicinal approach to reduce 
cholesterol in dyslipidaemia patients. Most of the natural 
product is started from the ethnic beliefs that have been 
claimed to have a medicinal effect. Same goes to EBN 
that have been consumed traditionally for metabolic 
stimulant by the royal family of China. Based on Yida 
et al. (2015a), EBN could reduce blood cholesterol in an 
insulin resistance animal model. Nevertheless, they were 
not further elaborated on by which the EBN is improving 
cholesterol. Therefore, this article reports the biological 
functions of EBNE on the cholesterol metabolism in 
HepG2 cells, as a preliminary study. This study will 
provide a better understanding on the potential role of EBN 
as an alternative food to reduce blood cholesterol in future.
MATERIALS AND METHODS
EBNE PREPARATION AND EXTRACTION
Edible bird’s nest was purchased from a certified 
manufacturer in a raw form before being soaked, and 
cleaned manually in the PBS (Phosphate Buffer Solution). 
Cleaned EBNs were pooled together and air dried in 
100% ventilated incubator at 30 °C for 24 h. Dried EBN 
was ground into a small granule using table top grinder 
before the extraction procedure. 1.0 g of dried EBN was 
soaked in 15 mL PBS and vortexed for 30 s. Soaked EBN 
were stewed in a pre-warmed water bath at 70 °C for 5 h, 
to get the EBN extract (EBNE). EBNE was centrifuged for 
10 min at 4,400 rpm. Supernatant was collected for protein 
precipitation via cold acetone technique. Finally, protein 
pellet was dissolved in 1.0 mL chilled PBS (4.0 °C) by re-
suspending with micropipette and vortexed. Final product 
was subjected for protein determination using BCA assay 
kits (Thermo Fisher Scientific, USA).
HepG2 CELL MAINTENANCE AND TREATMENT
HepG2 was purchased from American Type Culture 
Collection (ATCC) and maintained in Advanced Minimum 
Essential Medium (AMEM) supplemented with 10% 
FBS (Foetal Bovine Serum) as suggested from the 
manufacturer. Additional 1% Penicillin-Streptomycin 
and Fungizone (2.5 µg/mL) was added to avoid secondary 
infection. Cells were maintained in T-25 cell culture flask 
under humidified incubator at 37.0 °C with 5% CO2, until 
90% confluent before sub-cultured into different plate. 
Media were changed regularly for every two days while 
in maintenance phase. For treatment protocol, 1 × 106 cells 
were cultured in 6-wells plate sized 3.0 cm in diameter 
for 24 h before treatment was started. HepG2 cells were 
then cultured in AMEM and 1% FBS with or without 
exogenous cholesterol (1:250) and LDL-C (10 µg/mL), in 
the presence or absence of EBNE that already quantified 
at different concentrations (0.5, 1.0 and 1.5 mg/mL) for 
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24 h. Treatment regime consists of three controls which 
include baseline control (BC-media only), negative control 
(NC-media with exogenous cholesterol and LDL-C) and 
positive control (PC-media with exogenous cholesterol, 
LDL-C and anti-cholesterol drug (Simvastatin-4.60 µg/
mL)).
HepG2 CELL VIABILITY ASSAY
Cells were seeded in 96-wells microplate at 3 × 104 cells 
per well and treated with different concentrations of 
EBNEs (0.2, 0.5, 0.8, 1.0 and 1.5 mg/mL). After incubation 
for 24 h, treatment media was removed and replaced with 
new media containing AMEM and 1% FBS before 10 µL 
of MTT reagent (5 mg/mL) was added into the wells. 
Cells were incubated again for 4 h before discarding old 
media containing MTT reagent and replaced with 100 µL 
of DMSO. Cell viability curve was established and IC50 
was determined.
LDL-R, ACAT2 AND HMGCR mRNA EXPRESSION
Cell pellets were subjected for RNA extraction using 
Qiagen RNeasy® Mini Kit. RNA quality was determined 
using NanoQuant plate™ (Tecan, Switzerland) via Infinite 
M200Pro Spectrophotometer (Tecan, Switzerland). Total 
extracted RNA was standardized into 100 ng/µL before 
subjected for primers (Table 1) optimization in the 
Thermoblock 96 thermocycler (Sensoquest, Germany) 
using Access RT-PCR System master mix (Promega, 
USA), and electrophoretically validated in 1.5% agarose 
gel. Qualitative bands observation was visualized using 
Gel Doc XR+ System Image Analyser (Bio-Rad, USA) 
before optimized annealing temperature was determined. 
RNA was amplified using GoTaq® qPCR master mix 
(Promega, USA) according optimized LDL-R, ACAT2, 
HMGCR, and GADPH (housekeeping gene). At first, gene 
amplification was started with reverse transcription at 45 
°C for 45 min, followed by initial denaturation at 95 °C 
for 5 min. Both processes were done for one cycle only. 
Denaturation at 95 °C for 1 min, followed by annealing 
at 64 °C (LDL-R), 59 °C (ACAT2), 50 °C (HMGCR) and 64 
°C (GAPDH) for 1 min, and extension at 72 °C for 20 s 
were performed for 40 cycles. Final extension was setup 
at 72 °C for 7 min, followed by incubation at 4 °C were 
applied to all genes. The product size for LDL-R, ACAT2, 
HMGCR, and GAPDH are 369, 70, 210, and 453 base pair 
(bp), respectively. The ∆∆CT quantification was used to 
determine the expression of target genes using GADPH; as 
an internal control gene via CFX-96 Touch™ Real-Time 
PCR Detection System (BioRad, USA). Target gene mRNA 
level was expressed in relative-fold to the baseline 
control using the same system.
TABLE 1. Description of analysed genes in the in-vitro experimental study
Gene Name Description Forward (F) and Reverse (R) Primer Sequence (5’-3’) Accession 
Number
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For immunofluorescence staining, 1.0 × 103 HepG2 cells 
in 50 µL of media were cultured on top of round-cover 
slips inside 6-wells plate for 1 h in the CO2 incubator. Post 
cells attachment, media containing treatments were added 
in the well up to 2.0 mL and kept for 24-h. Old media was 
removed and replaced with 4% paraformaldehyde (PA) 
for fixation. PA was removed and cells were washed three 
times with 2.0 mL PBS for five minutes in each washing 
steps. Cells fixation continued for overnight in 4 °C with 
1% PA. Cells were washed again with PBS in the same 
manner before permeabilization of cells with 0.2% triton-X 
100 and subsequently soaked in a blocking solution of 2% 
BSA in PBS. Cover slips were incubated with 1:50 primary 
antibody (LDL-R) (ab52818, Abcam, UK) and secondary 
antibody (Alexa Fluor® 594 Donkey Anti-Rabbit IgG 
[H+L]). Lipid immunofluorescence staining (Bodipy 
493/503) was used to stain the lipid droplets and DAPI 
staining was used for nuclear staining. Cells were viewed 
with Nikon Eclipse Ti-S fluoroscopy (Nikon, Japan).
HepG2 INTRAHEPATOCELLULAR CHOLESTEROL 
QUANTIFICATION
Lipid extraction was performed on the treated and control 
cells by acidified Bligh and Dryer method. Cells were 
collected into the respective glass tubes with 0.5 mL PBS 
and homogenized with a TissueRuptor and Disposable 
Probes (Qiagen, Germany). About 100 µL of cell suspension 
were reserved for protein determination via BCA assay, 
and 500 µg of protein in 1.0 mL PBS was used for lipid 
extraction. Chloroform containing lipid extracts were 
evaporated with nitrogen gas flow in a pre-heated water 
bath at 55 °C. Cholesterol quantification was performed 
with a cholesterol assay kit from Cholesterol Liquicolor 
(Human Diagnostics Worldwide, Germany). Cholesterol 
concentration was determined via absorbent at 540 nm 
wavelength using Infinite M200Pro Spectrophotometer 
(Tecan, Switzerland). 
STATISTICAL ANALYSIS
Data were expressed in mean and standard deviation (SD) 
before data screening and normalization were conducted 
via normality test. Independent t-test was used for data 
analyses by comparing groups at p-value <0.05 to show 
significance differences between corresponding data.
RESULTS AND DISCUSSION
HepG2 CELL VIABILITY
HepG2 cell lines were selected in this study, as the 
cholesterol metabolism is mainly occurred in the liver 
(Rogers et al. 2015; Shimano & Sato 2017). Although 
the HepG2 is a human liver cancer cell lines, the usage 
of this cell is the most established and reported in-vitro 
model in assessing cholesterol metabolism in previous 
studies (Al-Naqeb et al. 2010; Chong et al. 2011; Leng 
et al. 2018; Nielsen et al. 2013; Zhao et al. 2016). Figure 
1 shows the effect of different EBNE concentrations (0.2, 
0.5, 0.8, 1.0 and 1.5 mg/mL) on the HepG2 cell viability 
post 24-h treatment. The cell viability for the respective 
concentration was 97.46 ± 1.52, 90.01 ± 2.62, 84.53 ± 
2.04, 77.56 ± 0.99 and 70.94 ± 1.52 (n=9). Therapeutic 
dosage of simvastatin (4.3 µg/mL) showed insignificant 
cell mortality (106.29 ± 3.92). The 50% inhibitory 
concentration (IC50) was unable to determine, as the 
cell line appeared viable more than 50% at the highest 
concentration (1.5 mg/mL). HepG2 was appeared to be 
viable at the highest concentration with 71% cell viability, 
and at 80% cell viability was calculated at 0.93 mg/mL. 
Since the HepG2 cell viability at 1.5 mg/mL was 71%, 
the cell viability test was not conducted at the higher 
concentration, and this justification is in line with previous 
study that mentioned, a good cell viability for in-vitro 
study must be maintained more than 70% (Al-Naqeb et al. 
2010). Meanwhile, 1.0 mg/mL of EBNE was 78%, which 
was correlated with previous data that shows the cell 
viability of HepG2 at 1.0 mg/mL of EBNE, can be up to 
80% (Yida et al. 2014). This finding is validated with recent 
study that shows EBN can serve as antioxidant mediator 
through transcriptional regulation of hepatocytes 
antioxidant gene in in-vitro and in-vivo model (Yida et 
al. 2015b, 2014), subsequently maintained the integrity 
and viability of the cell. This statement is supported with 
in vivo result that have shown the EBNE was not causing 
pathological changes in mice, and finally classified as 
category 5 or unclassified according to the GHC based on 
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OECD guidelines (Haghani et al. 2016). On the other type 
of cell line such as MDCK, IC50 of EBNE can be ranging 
between 2.9-4.5 mg/mL (Haghani et al. 2017), which can 
be considered high for a natural product origin. 
 
LDL-R, ACAT AND HMGCR GENE EXPRESSION
Gene expression is an initial point for the biochemical 
pathway regulation at the cellular level. Therefore, to 
investigate the effect of EBNE on cholesterol metabolism, 
quantitative PCR was done to measure the fold expression 
of several genes that are involved in cholesterol metabolism. 
Figure 2 shows the expression of gene of interest (GOI) 
FIGURE 1. Bar chart of the cell viability for HepG2 against EBN extract for 24 h. Graph 
was plotted at control, different concentration of EBN extract (0.2, 0.5, 0.8, 1.0 and 1.5 
mg/mL) and Simvastatin (4.3 µg/mL). Data with a different letter indicates significant 
differences when compared with control. Data were presented in means ± standard 
deviation (SD). Data with a different letter indicates significantly differences (n=9)
LDL-R via gel electrophoresis in each control (baseline 
(BC), negative (NC) and positive (PC) control) and EBNE 
treatments (0.5, 1.0 and 1.5 mg/mL). Qualitatively, all 
samples were expressing the LDL-R gene (369 bp). The 
intensity of the LDL-R band appeared in a dose-dependent 
manner; with 1.5 mg/mL of EBNE showed the most 
intensified band among the EBNE treatments. 
FIGURE 2.  The LDR-R gene expression in controls and EBNE treatments. Baseline control (BC) 
containing only media; negative control (NC) containing media, exogenous cholesterol and LDL-C; 
positive control (PC) containing media with exogenous cholesterol, LDL-C and Simvastatin; 0.5, 1.0 
and 1.5, respectively represents concentration of EBNE (0.5, 1.0 and 1.5 mg/mL) with exogenous 
cholesterol and LDL-C
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Figure 3 shows the fold expression of selected GOI 
(LDL-R, ACAT2, and HMGCR). All data were normally 
distributed and fold expression was expressed in mean 
(n=9) and standard deviation (SD). As presumed, the PC 
group was showing the highest fold expression (49.64 
± 8.26) compared to the BC. Meanwhile, the NC group 
demonstrated the lowest fold expression (3.24 ± 0.85). 
Negative control was used in this study to observe how the 
cell will react and survive in a high cholesterol environment 
without any treatment, and to show that normal human 
liver cell will survive and upregulates LDL-R expression 
significantly as a response to high cholesterol condition 
(Charlton-Menys & Durrington 2007), but not as efficient 
as cells supplemented with EBNE. In general, EBNE 
(0.5, 1.0 and 1.5 mg/mL) upregulates LDL-R expression 
significantly compared to the baseline control in a dose-
dependent manner (3.30 ± 0.78, 6.18 ± 2.57 and 7.41 ± 
3.04). 
For ACAT2, the PC showed the highest fold of 
gene expression (16.68 ± 0.25), and similar trend was 
demonstrated in the EBNE group (0.5, 1.0 and 1.5 
mg/mL) with positive dose dependent manner (2.05 
± 0.16, 3.78 ± 0.17 and 5.33 ± 0.16). This finding was 
corresponded with the expression of LDL-R. As the LDL-C 
had been internalized into the cell cytoplasm together 
with LDL-R inside the clathrin-coated endocytic vesicle, 
contained-LDL-C will undergo acidic hydrolysis to produce 
cholesterol and amino acid, before fused with endoplasmic 
reticulum (ER), and cholesterol will be hydrolysed by 
ACAT2 and causing increment of cholesteryl ester 
production in between of ER’s phospholipid bilayer 
(Chang et al. 2009; Martin & Parton 2006; Rogers et al. 
2015). This accumulation will lead to budding of new 
independent organelle such as lipid droplet that associated 
with specific protein on the monolayer phospholipid 
(Martin & Parton 2006).
HMGCR is a rate-limiting enzyme in cholesterol 
biosynthesis via mevalonate pathway (Shimano & Sato 
2017), and inhibition of this enzyme gain attention 
from researchers for the past decades in reducing high 
cholesterol in dyslipidaemic patient (Steinberg 2006). 
Previously, Vanillin Rich Fraction (VRF) was detected to 
downregulate HMGCR expression and upregulate LDL-R 
significantly in a dose dependent manner (Al-Naqeb et 
al. 2010). In general, EBNE (0.5, 1.0 and 1.5 mg/mL) 
downregulated HMGCR expression in negative dose 
dependent manner (0.88 ± 0.09, 0.73 ± 0.29 and 0.69 ± 
0.16). Nevertheless, only the highest concentration (1.5 
mg/mL) showed significant gene suppression at 31% 
compared to BC. Therefore, we suggest that the effective 
dosage for the EBNE to give an anti-cholesterol effect 
should be at 1.5 mg/mL. This finding is consistent with our 
laboratory collaborator, that had found serum paraoxonase/
lactonase 3 (PON-3) protein in our EBNE, which serves 
as prodrug of HMGCR inhibitor (Unpublished data). 
Insignificant finding in 0.5 and 1.0 mg/mL EBNE in the 
present study could be due to insufficient amount of PON-3 
protein in our extract to cause the anti-cholesterol effect. 
As expected, the Simvastatin was significantly suppressed 
the HMGCR gene at 65% and this finding was in line with 
the study by Charlton-Menys and Durrington (2007) on 










In order to visualize the LDL-R protein expression 
and the final product of internalized LDL in the lipid 
droplets (LDs), LDL-R, and LDs were enhanced 
with immunofluorescence-labelled antibody. In the 
immunofluorescence staining imaging, LDL-R, LDs, 
and nucleus were stained with red, green and blue, 
respectively (Figure 4). As the treatment concentration 
(EBNE) increased, the distribution of LDL-R fluorescence 
(red) was gradually increased on the cell lines, which 
indicated the abundant expression of the LDL-R protein 
on the membrane plasma. This finding was consistent with 
our expression analysis (Figure 3) and also validated the 
effect of EBNE in increasing the LDL-R protein expression 
in HepG2. For the controls, fluorescence distribution of 
the LDL-R in BC was observed in the absent of LDL-R 
expression. This could be explained as the media only 







 FIGURE 3. Bar chart of gene expression for (a) LDL-R, (b) ACAT2, and (c) HMGCR in HepG2 
cell lines against controls (BC; baseline control, NC; negative control, PC; positive control) 
and EBNE treatment groups (0.5, 1.0 and 1.5 mg/mL). Data were presented in means ± 
standard deviation (SD). Data with a different letter indicates significantly differences (n=9)
(cholesterol) that must be presence to initiate the LDL-R 
protein expression (Shimano & Sato 2017).
Conversely, positive control that contained media, 
exogenous stimulus, and Simvastatin showed the highest 
LDL-R distribution, as the Simvastatin increased the 
LDL-R protein expression upon the treatment (Chan et 
al. 2014). In correlation with high LDL-R fluorescence 
distribution, the LDs was gradually increased in size as 
the EBNE concentration increased, which means more 
exogenous cholesterol and LDL-C was internalized by 
the LDL-R, and stored in the LDs. This data was also 
consistent with the expression of ACAT2 (Figure 3). As 
the nature of hepatocytes to contain LDs in the cytoplasm 
(Rogers et al. 2015), baseline control was observed to have 
a tiny and smaller LDs compared to positive control which 
contained larger LDs; as Simvastatin upregulates LDL-R 
and increases storage of cholesterol particularly LDL-C 
(Charlton-Menys & Durrington 2007).
FIGURE 4. Microphotographs of immunofluorescence (IF) staining of LDL-R (red), LDs 
(green) and nucleus (blue) in controls (BC; baseline control, NC; negative control, PC; 
positive control) and EBNE (0.5, 1.0 and 1.5 mg/mL). Magnification 200X
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INTRAHEPATOCELLULAR CHOLESTEROL CONCENTRATION 
OF HepG2
Calorimetric assay (ELISA) was performed to quantify 
the cytosol cholesterol. Figure 5 shows cholesterol 
concentration of controls (BC, NC, and PC) and treated 
cells at different dosage of EBNE (0.5, 1.0 and 1.5 mg/
mL). All data were significantly increased compared to 
the BC. As expected, PC group that treated with anti-
cholesterol drug (Simvastatin) was recorded as the highest 
cholesterol concentration (129.0 ± 7.0), and this finding is 
consistent with the pharmacodynamic of statin drug group 
in lowering exogenous cholesterol (Steinberg 2006), and 
stored in the lipid droplets (Chang et al. 2009). Conversely, 
BC recorded the lowest cholesterol concentration (7.0 
± 2.0), and this result was predicted earlier as there is 
pre-existing cholesterol in the hepatocytes that made 
up the plasma membrane of cell and organelles, and the 
lipid droplets (Gartner 2017). In the NC, the cholesterol 
concentration (12.0 ± 1.0) was slightly increased 
compared to the BC, as the normal physiological function 
of the hepatocytes will increase internalization of excess 
cholesterol for lowering the exogenous cholesterol in 
order to maintain the homeostatic condition (Charlton-
Menys & Durrington 2007). Nevertheless, the uptake 
might be less due to limited LDL-R expression on the 
outer layer of plasma membrane. For the EBNE treated 
cells, cholesterol concentrations were expressed in a 
dose-dependent manner (15.0 ± 3.0, 32.0 ± 7.0, and 
96.0 ± 2.0). These results were parallel with our ACAT2 
expression (Figure 3), which indicate that the EBNE 
able to increase internalization of excessive exogenous 
cholesterol, and may contribute to the cholesterol storage 
in the lipid droplets (Rogers et al. 2015). Besides that, this 
finding also supported by previous study that suggests 
the present of sialic acid in the EBN (Yida et al. 2015a) is 
imperative in preventing oxidation of exogenous LDL-C 
and in preserving the conformation of this lipoprotein 
which lead to the consistent internalization of LDL-C into 
the cytosol (Lindbohm et al. 2000; Millar 2001). From the 
data, the negative control showed insignificant difference 
with 0.5 mg/mL of EBNE. This finding suggests that, to 
have an effect for internalization of excessive exogenous 
cholesterol for storage, the EBNE dose must be higher 
than 0.5 mg/mL and this will be the benchmark for further 
in-vivo study.
FIGURE 5. Bar chart of gene expression for (a) LDL-R, (b) 
ACAT2, and (c) HMGCR in HepG2 cell lines against controls 
(BC; baseline control, NC; negative control, PC; positive 
control) and EBNE treatment groups (0.5, 1.0 and 1.5 mg/mL). 
Data were presented in means ± standard deviation (SD). Data 
with a different letter indicates significantly differences (n=9)
Based on the results, we propose a schematic 
diagram (Figure 6) on by which the EBNE improved 
the cholesterol metabolism. Upon supplementation 
of EBNE, suppression of the HMGCR gene that acts 
as cholesterol rate-limiting enzyme will lead to the 
intracellular cholesterol deprivation. As the internal 
regulatory responses, the LDL-R gene will be upregulated 
to restore the homeostatic cholesterol level inside the 
cell. The LDL-R will allow the internalization of excess 
exogenous cholesterol into the cytoplasm, particularly the 
LDL-C. This LDL-C will be transported to the endoplasmic 
reticulum for further storage inside the new lipid droplets 
(LDs), under catalyzation of ACAT2 enzyme. These 
newly biosynthesis LDs will be utilized for further cellular 
physiology.
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FIGURE 6. A proposed schematic pathway for Edible Bird’s Nest Extract (EBNE) supplementation 
in reducing cholesterol on the human liver cell lines (HepG2). EBNE supplementation causes 
down-regulation of cholesterol rate-limiting enzymes gene expression (HMGCR; 3-hydroxy-3-
methyglutharyl-coenzyme A reductase) on the endoplasmic reticulum (ER) (1), and resulting in 
deprivation of intra-hepatocellular cholesterol concentration in the cytosol. As a homeostatic 
negative feedback mechanism, LDL-R (low-density lipoprotein receptors) gene expression is up-
regulated (2) to restore back cholesterol deficiency in the cytosol, via internalization of exogenous 
LDL-C. Internalized-LDL-C will be transported in the lysosome and metabolized via acidic 
hydrolysis to form hydrolysed free cholesterol and some amino acids. Hydrolysed free cholesterol 
is directly transported to the endoplasmic reticulum for storage under catalyzation of ACAT2 (acyl-
coenzyme A: cholesteryl acyltransferase 2) gene that is also up-regulated (3) for the hydrolysed 
cholesterol to be stored in the form of cholesteryl esters. Accumulation of cholesteryl esters in the 
intramembrane of endoplasmic reticulum will lead to newly synthesis of lipid droplets budding and 
will be released into the hepatic cytosol (4)
CONCLUSION
In conclusion, EBNE could upregulate LDL-R and ACAT2 
expressions in a positive dose-dependent manner, and 
suppressed HMGCR expression significantly at the highest 
concentration. These resulted in formation of abundant 
lipid droplet from numerous expression of LDL-R protein 
on the plasma membrane, and dramatically increased the 
cholesterol concentration upon EBNE supplementation in 
a dose-dependent manner. This finding provides an insight 
in elucidating the effect of EBNE on the cardiovascular 
health in animal model. 
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